Search
Displaying 211–220 of 1059 results for “fc 26 ps4 coins Visit Buyfc26coins.com for latest FC 26 coins news..NH7v”
-
Advocacy Research News
In this in-depth interview hosted by InVivo, Jason Menzo, CEO of the Foundation Fighting Blindness, outlines the organization’s strategy for addressing significant changes and opportunities in the inherited retinal diseases (IRDs).
-
Safety Clinical Trial Launched for Usher Syndrome 3 Drug
Research NewsResearchers hope the molecule will slow the vision and hearing loss associated with USH3.
-
4DMT Planning Phase 3 Clinical Trial for Wet AMD Gene Therapy
Research NewsKnown as 4D-150, the wet AMD gene therapy performed well in a Phase 2b clinical trial.
-
Beacon Doses First Patient in its Phase 2/3 VISTA Clinical Trial for XLRP Gene Therapy
Research NewsThe company plans to apply for regulatory approval for the gene therapy with data from VISTA and its earlier clinical trials.
-
SalioGen Developing Novel Gene Insertion Therapy for Stargardt Disease
Research NewsThe company’s innovative Gene Coding™ platform enables seamless insertion of DNA into selective genomic locations.
-
Fundraiser Success Stories
Lindsey Blankenship, president of the Foundation Fighting Blindness Colorado Chapter, has created a one-of-a-kind Raising Our Sights Event. Wine for a Cure aims to spread awareness and fundraise on behalf of the Foundation Fighting Blindness with two signature wines from the Oregon Winery, Stoller Family Estates. The featured wines are a Chardonnay named “Variant” and a Pinot Noir named “Pigmentosa.”
-
Research News
The company is planning a late-stage trial for its achromatopsia (CNGB3) gene therapy.
-
Investigators Report Partial Vision Restoration for One Patient in Optogenetic Therapy Trial
Research NewsThe gene-agnostic approach is designed to restore some vision to people with advanced vision loss
-
Encouraging Early Report for Three Patients in LCA1-GUCY2D Gene Therapy Clinical Trial
Research NewsDevelopment of the emerging gene therapy is being funded by the Foundation’s RD Fund
-
Genentech’s Faricimab Performs Well in Phase 3 Clinical Trials for Wet AMD
Research NewsCompany will seek marketing approval for the emerging therapy
